Intranasal thermosensitive gel for rasagiline mesylate (RM) was developed for effective treatment of Parkinson's disease. Intranasal gels were prepared by combination of poloxamer 407 and poloxamer 188 (1:1) with mucoadhesive polymers (carbopol 934 P and chitosan). The formulations were evaluated for sol-gel transition temperature, in-vitro drug release and in-vivo mucociliary transit time. Further, optimal intranasal gel formulations were tested for in-vivo pharmacokinetic behavior, nasal toxicity studies and brain uptake studies. It was found that optimal formulations had acceptable gelation temperature (28-33 °C) and adequate in-vitro drug release profile. Pharmacokinetic study in rabbits showed significant (p < 0.05) improvement in bioavailability (four- to six-folds) of the drug from intranasal gels than oral solution. Chronic exposure studies in Wistar rats showed that these intranasal gels were non-irritant and non-toxic to rat nasal mucosa. Estimation of RM in rat brain tissue showed significant (p < 0.01) improvement in uptake of RM form intranasal gel formulations than nasal solution.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10717544.2013.860501 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of paroxetine loaded nanotransferosomal gel for intranasal delivery with enhanced antidepressant activity in rats.
Colloids Surf B Biointerfaces
February 2025
Department of Pharmaceutics, Faculty of Pharmacy, Al-Baha University, Al-Baha, Saudi Arabia.
The aim of this study was to develop paroxetine (PXT) loaded nanotransferosomal gel (PXT-NTFG) for intranasal brain delivery. The process involved fabricating PXT-NTFs (paroxetine-loaded nanotransferosomes) through a thin film hydration method and optimizing them based on parameters such as particle size (PS), zeta potential (ZP), polydispersity index (PDI), and entrapment efficiency (EE). The optimized PXT-NTFs exhibited uniform morphology with a PS of 158.
View Article and Find Full Text PDFAdvancement in the Nose-to-Brain Drug delivery of FDA-approved drugs for the better management of Depression and Psychiatric disorders.
Int J Pharm
December 2024
Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Kishangarh, Ajmer 305817, Rajasthan, India. Electronic address:
The Prevalence of Depressive and Psychiatric disorders is increasing globally, and despite the availability of numerous FDA-approved drugs, treatment remains challenging. Many conventional antidepressants and antipsychotic formulations face issues such as low solubility, high first-pass metabolism, poor bioavailability, inadequate blood-brain barrier penetration, and systemic side effects. These challenges lead to reduced efficacy, slower onset of action, and decreased patient adherence to treatment.
View Article and Find Full Text PDFA coloaded liposome in situ gel as a novel therapeutic strategy to treat cerebral ischemia reperfusion injury.
Brain Res
January 2025
Department of Neurology, Liaocheng People's Hospital, Liaocheng 252000, Shandong, China; Department of Neurology, Liaocheng People's Hospital, Shandong University, Jinan 250012, Shandong, China; Department of Neurology, the Second People's Hospital, Liaocheng, Liaocheng 252000, Shandong, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, Shandong Sub-centre, Liaocheng 252000, Shandong, China. Electronic address:
Background: Ischemic stroke has become one of the leading causes of death and disability worldwide in individuals aged 60 and above. However, currently available drugs show limited efficacy. Therefore, research to find more effective and safer therapeutic strategies is an urgent requirement for the treatment of cerebral ischemia reperfusion injury (CIRI).
View Article and Find Full Text PDFEvaluation of Mucoadhesive Nano-Bilosomal In Situ Gels Containing Anti-Psychotic Clozapine for Treatment of Schizophrenia: In Vitro and In Vivo Studies.
Pharmaceuticals (Basel)
October 2024
Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Patients with schizophrenia have significant challenges in adhering to and complying with oral medicines, resulting in adverse consequences such as symptom worsening and psychotic relapse. This study aimed to develop clove oil-based bilosomes using definitive screening design (DSD) to maximize the anti-schizophrenic action of clozapine and promote its nose-to-brain delivery. The target was to optimize the physicochemical properties of bilosomes and incorporate them into mucoadhesive intranasal in situ gels, searching for augmented ex vivo and in vivo clozapine delivery.
View Article and Find Full Text PDFParoxetine Loaded Nanostructured Lipid Carriers Based In-situ Gel for Brain Delivery via Nasal Route for Enhanced Anti-Depressant Effect: In Vitro Prospect and In Vivo Efficacy.
AAPS PharmSciTech
October 2024
Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, 23200, Pakistan.
Article Synopsis
- - The study developed a thermosensitive gel using nanostructured lipid carriers (NLCs) loaded with paroxetine for nasal delivery to improve depression treatment, employing a microemulsion technique for preparation.
- - The optimized NLCs had a high entrapment efficiency of around 90%, and showed favorable characteristics, such as a particle size of 155 nm and a gelling temperature suitable for nasal use (31.5°C).
- - In vivo tests indicated that the paroxetine-loaded NLC gel was more effective in treating depression than the standard NLCs, enhancing brain tissue architecture and reducing inflammatory markers, demonstrating potential for better management of depression through nasal administration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!